Haemonetics Co. (NYSE:HAE) Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its position in shares of Haemonetics Co. (NYSE:HAE) by 22.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 25,932 shares of the medical instruments supplier’s stock after acquiring an additional 4,672 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Haemonetics were worth $2,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in HAE. ProShare Advisors LLC raised its holdings in shares of Haemonetics by 4.7% during the first quarter. ProShare Advisors LLC now owns 11,490 shares of the medical instruments supplier’s stock worth $981,000 after purchasing an additional 516 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Haemonetics by 15.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,475 shares of the medical instruments supplier’s stock valued at $1,363,000 after buying an additional 2,160 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Haemonetics during the first quarter worth about $1,723,000. Covestor Ltd lifted its holdings in Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Haemonetics by 13.2% in the first quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier’s stock valued at $4,330,000 after acquiring an additional 5,933 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

Shares of NYSE HAE opened at $89.24 on Friday. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The firm has a 50-day moving average of $77.23 and a two-hundred day moving average of $82.77. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 1.43 and a beta of 0.32.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $0.99 earnings per share. As a group, analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HAE has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research report on Friday. Bank of America began coverage on shares of Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective on the stock. BTIG Research assumed coverage on shares of Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price for the company. Citigroup dropped their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.